All In Biotech

Drug Trial Radar · NCT06540963

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

98

Planned (sponsor's estimate)

Start

Dec 6, 2024

Primary completion

Dec 1, 2030

Study completion Dec 1, 2035

Sponsor

Lead sponsor
Giselle ShollerAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the investigational drug, tipifarnib (a pill taken by mouth), in combination with the Food and Drug Administration (FDA) approved drug, naxitimab, administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been placed during a surgery into one of your veins). Naxitamab is FDA approved for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy, it may not be approved in the type of disease used in this study. The goals of this part of the study are: * Test the safety and tolerability of tipifarnib in combination with naxitimab in participants with cancer * To determine the activity of study treatments chosen based on: * How each participant responds to the study treatment * How long a participant lives without their disease returning/progressing

Conditions

  • Neuroblastoma

Interventions

  • TipifarnibDrug

    Tablet

  • NaxitamabDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the Overall Response Rate (ORR) of Participants using INSS ResponseTime frame: 6 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • Connecticut Children's Hospital

    Hartford, Connecticut · Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Recruiting

  • Arnold Palmer Hospital for Children

    Orlando, Florida · Recruiting

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii · Recruiting

  • Cardinal Glennon Children's Medical Center

    St Louis, Missouri · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • Randall Children's Hospital

    Portland, Oregon · Recruiting

  • Penn State Milton S. Hershey Medical Center and Children's Hospital

    Hershey, Pennsylvania · Recruiting

  • Monroe Carrell Jr. Children's Hospital at Vanderbilt

    Nashville, Tennessee · Recruiting

  • Dell Children's Blood and Cancer Center

    Austin, Texas · Recruiting

  • Children's Medical Center

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.